No need to apolgise. You're posts and differing views are good for robust discussion.
You asked, "What's the $3m in savings derived from , isn't this a phase 1 clinical trial?"
I was referring to the costs of both panic disorder and pain indication trials including the phase 2 trials.
Under the agreement, iNGENu CRO will design and execute the following clinical studies: Phase I Study in Healthy Volunteers - Inhaled THC Drug/Device Combination
Phase II Study in CRPS Patients - Inhaled THC Drug/Device Combination
Phase II Study in Panic Disorder Patients - Inhaled CBD Drug/Device Combination
The panic disorder trial looks to be slightly more expensive so if money is challenging, focusing on one clinical study could also be an option.
Dr Sud is a rookie? I don't think there is a more qualified or bigger name in the Australian cannabis sector than Dr Sud. His success in transforming IHL from a mouthguard company at something like 2 cents into a bio-pharma that hit 70 cents and almost a billion dollars in market cap speaks for itself.
I note among Dr Sud's contacts on the IRX register is the Pisciotta family, the co-founder of Carsales so I'd say there is a level of trust in Dr Sud in the investment community.
Even a quick glance at Ingenu's Linkedin shows they are winning customers; just because you're less experienced than the next guy doesn't mean you can't excell at what you do.
The shareholders voted 99% for Ingenu. It says it all.
